Zoetis Inc. $ZTS Shares Sold by Novare Capital Management LLC

Novare Capital Management LLC reduced its stake in shares of Zoetis Inc. (NYSE:ZTS) by 8.8% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 87,733 shares of the company’s stock after selling 8,438 shares during the quarter. Novare Capital Management LLC’s holdings in Zoetis were worth $12,837,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently bought and sold shares of ZTS. North Star Asset Management Inc. raised its stake in shares of Zoetis by 4.9% during the second quarter. North Star Asset Management Inc. now owns 1,441 shares of the company’s stock valued at $225,000 after purchasing an additional 67 shares during the period. Moment Partners LLC grew its holdings in Zoetis by 3.2% during the 2nd quarter. Moment Partners LLC now owns 2,354 shares of the company’s stock valued at $367,000 after purchasing an additional 72 shares in the last quarter. CVA Family Office LLC increased its stake in Zoetis by 6.7% during the 2nd quarter. CVA Family Office LLC now owns 1,173 shares of the company’s stock worth $183,000 after buying an additional 74 shares during the period. Bank of Nova Scotia Trust Co. lifted its holdings in Zoetis by 4.6% in the 2nd quarter. Bank of Nova Scotia Trust Co. now owns 1,692 shares of the company’s stock worth $264,000 after buying an additional 74 shares in the last quarter. Finally, Country Club Bank boosted its position in Zoetis by 1.5% in the 2nd quarter. Country Club Bank now owns 5,142 shares of the company’s stock valued at $803,000 after buying an additional 75 shares during the last quarter. 92.80% of the stock is owned by institutional investors and hedge funds.

Zoetis Trading Up 0.8%

Shares of NYSE ZTS opened at $124.95 on Wednesday. Zoetis Inc. has a 12-month low of $115.25 and a 12-month high of $177.40. The company has a market cap of $55.06 billion, a price-to-earnings ratio of 21.04, a price-to-earnings-growth ratio of 2.15 and a beta of 0.97. The company has a current ratio of 3.64, a quick ratio of 2.28 and a debt-to-equity ratio of 1.31. The stock’s 50 day simple moving average is $123.81 and its 200 day simple moving average is $137.69.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Tuesday, November 4th. The company reported $1.70 EPS for the quarter, topping analysts’ consensus estimates of $1.62 by $0.08. Zoetis had a return on equity of 57.19% and a net margin of 28.21%.The firm had revenue of $2.40 billion during the quarter, compared to the consensus estimate of $2.42 billion. During the same period in the prior year, the business earned $1.58 EPS. The firm’s revenue was up .5% on a year-over-year basis. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Equities research analysts expect that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 3rd. Investors of record on Tuesday, January 20th will be given a $0.53 dividend. The ex-dividend date is Tuesday, January 20th. This represents a $2.12 annualized dividend and a yield of 1.7%. This is a boost from Zoetis’s previous quarterly dividend of $0.50. Zoetis’s payout ratio is 35.69%.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on ZTS shares. Bank of America lowered Zoetis from a “buy” rating to a “neutral” rating and set a $135.00 target price on the stock. in a research report on Monday, December 15th. JPMorgan Chase & Co. dropped their price objective on Zoetis from $230.00 to $200.00 and set an “overweight” rating on the stock in a report on Wednesday, November 5th. Barclays assumed coverage on Zoetis in a research note on Monday, December 8th. They set an “equal weight” rating and a $136.00 target price for the company. Piper Sandler restated a “neutral” rating and issued a $135.00 price target (down previously from $190.00) on shares of Zoetis in a research note on Thursday, January 22nd. Finally, Stifel Nicolaus reduced their price objective on shares of Zoetis from $140.00 to $130.00 and set a “hold” rating on the stock in a research note on Tuesday, November 18th. Five analysts have rated the stock with a Buy rating and eight have given a Hold rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $152.91.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.